研究について【2015年】

英文原著論文 Original papers

発刊済のものはabstractまたは本文にリンクしてあります。

Published papers are linked to PubMed


Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y.
Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus.
Rheumatology (Oxford). 2015 Mar;54(3):405-12.




Chihara D, Asano N, Ohmachi K, Nishikori M, Okamoto M, Sawa M, Sakai R, Okoshi Y, Tsukamoto N, Yakushijin Y, Nakamura S, Kinoshita T, Ogura M, Suzuki R.
Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).
Ann Oncol. 2015 May;26(5):966-73.




Nakajima A, Masaki Y, Nakamura T, Kawanami T, Ishigaki Y, Takegami T, Kawano M, Yamada K, Tsukamoto N, Matsui S, Saeki T, Okazaki K, Kamisawa T, Miyashita T, Yakushijin Y, Fujikawa K, Yamamoto M, Hamano H, Origuchi T, Hirata S, Tsuboi H, Sumida T, Morimoto H, Sato T, Iwao H, Miki M, Sakai T, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Umehara H.
Decreased Expression of Innate Immunity-Related Genes in Peripheral Blood Mononuclear Cells from Patients with IgG4-Related Disease.
PLoS One. 2015 May 14;10(5):e0126582.




Onishi S, Adnan E, Ishizaki J, Miyazaki T, Tanaka Y, Matsumoto T, Suemori K, Shudou M, Okura T, Takeda H, Sawasaki T, Yasukawa M, Hasegawa H.
Novel Autoantigens Associated with Lupus Nephritis.
PLoS One. 2015 Jun 22;10(6):e0126564.




Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R.
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Br J Haematol. 2015 Jun;169(5):672-82.




Suemori K, Hasegawa H, Ishizaki J, Matsumoto T, Onishi S, Sada E, Sugita A, Yasukawa M.
Methotrexate-associated Lymphoproliferative Disease with Multiple Pulmonary Nodules in a Patient with Rheumatoid Arthritis.
Intern Med. 2015;54(11):1421-5.




Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H, Tohma S, Yamanishi Y, Hasegawa H, Tanimura K, Negoro N, Ueki Y, Kawakami A, Eguchi K, Saito K, Okada Y.
Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.
J Bone Miner Metab. 2015 Aug 26. [Epub ahead of print]




Ichinose A, Osaki T, Souri M; Japanese Collaborative Research Group (JCRG) on AH13 (supported by the Japanese Ministry of Health, Labor, and Welfare).
Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies.
Haemophilia. 2015 Sep;21(5):653-8.




Ochi T, Nakatsugawa M, Chamoto K, Tanaka S, Yamashita Y, Guo T, Fujiwara H, Yasukawa M, Butler MO, Hirano N.
Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Cancer Immunol Res. 2015 Sep;3(9):1070-81.




Yamanouchi J, Hato T, Kunishima S, Niiya T, Nakamura H, Yasukawa M.
A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia.
Ann Hematol. 2015 Sep;94(9):1599-600.




Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.
Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Leukemia. 2015 Dec;29(12):2393-401.




Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee.
2015 Guidance on cancer immunotherapy development in early-phase clinical studies.
Cancer Sci. 2015 Dec;106(12):1761-71.